Navigation Links
IMMUNE 3D® Expands Platform into New Disease Areas and Enters into Drug Discovery
Date:5/14/2019

IMMUNE 3D®, a privately held biotechnology company, announced today an expansion of their business strategy beyond immuno-oncology into areas of autoimmunity, fibrosis and skin immunology. In addition, the company will leverage its proprietary, matched autologous human T cell and tumor cell lines for IO discovery efforts.

IMMUNE 3D®’s proprietary platform aims to study factors that affect immune migration under complex physiological conditions. The company utilizes the platform in areas of drug target discovery, characterization, biomarker identification and drug delivery testing.

"The increase in preclinical research and development spending has steered biopharmaceutical companies towards finding cost-effective alternatives beyond traditional in vivo models,” said Vik Subbu, Founder and CEO of IMMUNE 3D®. “This has paved the way for ex vivo platforms such as IMMUNE 3D® to be used across areas of preclinical studies and translational drug development.“

"IMMUNE 3D® provides unique insights into the tumor immune-microenvironment. Importantly, this platform can assess the efficacy of a wide variety of therapeutic approaches beyond immune checkpoints including the evaluation of CAR-T therapies in solid tumors,” said Dr. Tonya Webb, Associate Professor of Microbiology and Immunology, at the University of Maryland, Baltimore and scientific advisor to IMMUNE 3D®.

IMMUNE 3D® aims to build on its extensive know-how and intellectual property to develop proprietary 3D models across broad immune-mediated diseases. The company has profiled targets that facilitate immune migration using its proprietary human T cell and tumor cell lines. These targets have the potential to serve as novel therapies across a variety of human disorders such as cancer, autoimmunity and infectious diseases.

About IMMUNE 3D®
IMMUNE 3D®'s proprietary platform, provides a unique and powerful tool to interrogate immunobiology of diseases. The Company’s mission is to shift the paradigm towards a wider use of 3D cultures in translational research while accelerating much needed drug candidates into the clinic. The company has assembled a network of key opinion leaders, academic partnerships, board members and industry scientists to advance its platform.
http://www.immune3d.com

Read the full story at https://www.prweb.com/releases/immune_3d_expands_platform_into_new_disease_areas_and_enters_into_drug_discovery/prweb16301402.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. uBiome Receives Patent for Microbiome-Derived Diagnostics and Therapeutics for Immune-Microbial Dysfunction
2. Trivedi Global, Inc. and Maire Mayne Announce Research Results on the Impact of a Biofield Energy Treated Nutraceutical to Combat Inflammation and Autoimmune Disorders
3. Trivedi Global, Inc. and Dr. William Plikerd Announce Research on Impact of a Biofield Energy Treated Nutraceutical for Decreasing Inflammation and Autoimmune Disorders
4. Trivedi Global, Inc. with Inthirani Arul, Announce Research Results on the Impact of a Biofield Energy Nutraceutical for Reducing Inflammation and Autoimmune Disorders
5. IBM: Your Computer Can Help Scientists Study Connection Between Body Bacteria and Autoimmune Diseases
6. TapImmune Completes Scale-Up and GMP Manufacturing of TPIV 200 Vaccine to Supply Additional Phase 2 Clinical Trials
7. Oncimmune Signs Agreement with Leading Provider of Preventative Health Screenings
8. PNAS: From HIV to cancer, IL-37 regulates immune system
9. House fly genome reveals expanded immune system
10. Scientists question fundamental theory about education of immune police
11. Adolescent exposure to thc may cause immune systems to go up in smoke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2019)... LAKE CITY, and MARTINSRIED, Germany (PRWEB) , ... ... ... in high-throughput antibody screening and characterization, announced today that they have opened a ... Carterra’s platform has fueled the need for the new office. , The Munich ...
(Date:8/14/2019)... JOLLA, Calif. (PRWEB) , ... August 14, 2019 , ... ... insight into their future children, announces inclusion in the 38th annual Inc. 500|5000 ... been eligible to apply. To qualify, companies must have been founded and generating revenue ...
(Date:8/9/2019)... ... August 09, 2019 , ... With a demand in healthcare to ... patients will visit urgent care centers (UCC) in the coming years, according to a ... The Market for Urgent Care Centers , is a detailed look at the current ...
Breaking Biology News(10 mins):
(Date:9/2/2019)... DENVILLE, N.J. and LIÉGE, Belgium (PRWEB) , ... ... ... provider of solutions for epigenetics research and in vitro diagnostics, has launched the ... to uncover the underlying biological meaning of epigenetic data and other data ...
(Date:8/29/2019)... ... August 29, 2019 , ... ... in the Sustainable Medicines in Africa program, which includes a master’s degree in ... Arusha, Tanzania September 2nd through 13th, 2019. Topics to be addressed include ...
(Date:8/25/2019)... VEGAS (PRWEB) , ... August 23, 2019 , ... ... with International No. 1 best-selling status for the scientific research book “Impact of ... in the cosmetic and perfume industry as Patchouli. , The book garnered ...
(Date:8/15/2019)... (PRWEB) , ... August 15, 2019 , ... ... Scientific Advisory Board. Mr. Lawrence is a member of the Institute of Food ... Safety and Health (IFSH) Advisory Board, Joint Institute for Food Safety and Applied ...
Breaking Biology Technology: